IL154185A0 - Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug - Google Patents

Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Info

Publication number
IL154185A0
IL154185A0 IL15418501A IL15418501A IL154185A0 IL 154185 A0 IL154185 A0 IL 154185A0 IL 15418501 A IL15418501 A IL 15418501A IL 15418501 A IL15418501 A IL 15418501A IL 154185 A0 IL154185 A0 IL 154185A0
Authority
IL
Israel
Prior art keywords
cytokine
selectokine
target
fusion protein
antibody
Prior art date
Application number
IL15418501A
Other languages
English (en)
Original Assignee
Univ Stuttgart
Klaus Pfizenmaier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart, Klaus Pfizenmaier filed Critical Univ Stuttgart
Publication of IL154185A0 publication Critical patent/IL154185A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL15418501A 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug IL154185A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (1)

Publication Number Publication Date
IL154185A0 true IL154185A0 (en) 2003-07-31

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15418501A IL154185A0 (en) 2000-09-15 2001-09-17 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Country Status (22)

Country Link
US (1) US20040053829A1 (de)
EP (1) EP1317556A1 (de)
JP (1) JP2004508828A (de)
KR (1) KR20030048041A (de)
CN (1) CN1214115C (de)
AU (1) AU2001293819A1 (de)
BG (1) BG107613A (de)
BR (1) BR0113928A (de)
CA (1) CA2422759A1 (de)
DE (1) DE10045592A1 (de)
EE (1) EE200300100A (de)
HR (1) HRP20030192A2 (de)
HU (1) HUP0301693A3 (de)
IL (1) IL154185A0 (de)
MX (1) MXPA03002229A (de)
NO (1) NO20031185L (de)
PL (1) PL360540A1 (de)
RU (1) RU2003106429A (de)
SK (1) SK2812003A3 (de)
WO (1) WO2002022833A1 (de)
YU (1) YU18903A (de)
ZA (1) ZA200302008B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
RU2005127664A (ru) * 2003-02-06 2006-09-10 Микромет Аг (De) Тримерная полипептидная конструкция, индуцирующая пролонгированный т-клеточный ответ
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1736482A1 (de) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Rekombinanter trimerer 4-1BB Ligand
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (de) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Duales Targeting-System
EP2009022A1 (de) * 2007-06-26 2008-12-31 Apogenix GmbH Trimere Todesliganden mit erhöhter Aktivität (Tenascin)
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2010096838A2 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Llc Proproteins and methods of use thereof
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
MX2020012248A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2019222295A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
EP4321530A2 (de) 2018-09-27 2024-02-14 Xilio Development, Inc. Maskierte cytokinpolypeptide
JP2022532217A (ja) 2019-05-14 2022-07-13 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
WO2020252264A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
BR0113928A (pt) 2003-07-22
YU18903A (sh) 2006-05-25
EE200300100A (et) 2005-02-15
KR20030048041A (ko) 2003-06-18
BG107613A (bg) 2003-12-31
RU2003106429A (ru) 2004-08-27
DE10045592A1 (de) 2002-03-28
SK2812003A3 (en) 2003-11-04
MXPA03002229A (es) 2005-06-20
WO2002022833A1 (de) 2002-03-21
HUP0301693A2 (hu) 2003-08-28
JP2004508828A (ja) 2004-03-25
CN1214115C (zh) 2005-08-10
CN1458977A (zh) 2003-11-26
NO20031185D0 (no) 2003-03-14
US20040053829A1 (en) 2004-03-18
EP1317556A1 (de) 2003-06-11
HUP0301693A3 (en) 2005-11-28
NO20031185L (no) 2003-05-05
PL360540A1 (en) 2004-09-06
ZA200302008B (en) 2004-06-25
AU2001293819A1 (en) 2002-03-26
CA2422759A1 (en) 2003-03-17
HRP20030192A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
HUP0301693A3 (en) Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
EP1314437A4 (de) Antikörper enthaltende stabilisierte präparate
MXPA03002297A (es) Compuestos de triazol utiles como inhibidores de proteina cinasa.
HUP0302529A3 (en) Glp-1 fusion proteins
EP1276856A4 (de) Albumin fusionsproteine
AU2001291049A1 (en) Defensin-antigen fusion proteins
GB0019454D0 (en) Laser system
GB0015426D0 (en) Method for generating soluble highly multimeric proteins
GB0022079D0 (en) Novel protein tyrosine phosphatase inhibitor
AU2001291050A1 (en) Viral chemokine-tumur antigen fusion proteins
ATE264396T1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
IL150570A0 (en) Methods for protein transfer
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2002219974A1 (en) Immunoglobulin superfamily proteins
AU2002254529A1 (en) Nucleic acids for transgene expression
EP1179592A4 (de) Nectin-3 proteine
AU2002215161A1 (en) An assay for rhabdovirus inhibitors
GB2364167B (en) Laser system
AU2002232822A1 (en) Nucleic acid-associated proteins
GB0027308D0 (en) Drug-activated proteins
GB0020794D0 (en) Humanised antibodies
ZA200301704B (en) Triazole compounds useful as protein kinase inhibitors.
AU2001297737A1 (en) Nucleic acid-associated proteins
GB0018125D0 (en) Novel proteins
GB0018126D0 (en) Novel proteins